Literature DB >> 18448838

Modification of vimentin: a general mechanism of nonenzymatic glycation in human skin.

Thomas Kueper1, Tilman Grune, Gesa-Meike Muhr, Holger Lenz, Klaus-Peter Wittern, Horst Wenck, Franz Stäb, Thomas Blatt.   

Abstract

In a recent study, we were able to show that the intermediate filament protein vimentin aggregates in human dermal fibroblasts because of modification by the advanced glycation endproduct carboxymethyllysine (CML). In this work, we investigated the formation of intracellular CML in relation to the concentration of glucose in the culture medium. The natural degradation product of glucose, methylglyoxal, was able to induce the aggregation of vimentin. This dicarbonyl leads to the formation of the modifications MG-H1 and carboxyethyllysine (CEL) as a result of the reaction with arginine and lysine residues of proteins. Furthermore, we found that the protein vimentin was modified, not only by CML and CEL, but also by pentosidine and pyrraline. These findings underline the special position of vimentin as a preferential target of the Maillard reaction in human skin.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18448838     DOI: 10.1196/annals.1433.039

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  2 in total

1.  Derivation and characterization of cell cultures from the skin of the Indo-Pacific humpback dolphin Sousa chinensis.

Authors:  Wei Jin; Kuntong Jia; Lili Yang; Jialin Chen; Yuping Wu; Meisheng Yi
Journal:  In Vitro Cell Dev Biol Anim       Date:  2013-05-10       Impact factor: 2.416

2.  Glyoxalase 1-knockdown in human aortic endothelial cells - effect on the proteome and endothelial function estimates.

Authors:  Bernd Stratmann; Britta Engelbrecht; Britta C Espelage; Nadine Klusmeier; Janina Tiemann; Thomas Gawlowski; Yvonne Mattern; Martin Eisenacher; Helmut E Meyer; Naila Rabbani; Paul J Thornalley; Diethelm Tschoepe; Gereon Poschmann; Kai Stühler
Journal:  Sci Rep       Date:  2016-11-29       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.